Paushak Q4 Results FY26: PAT Rs 13 Crore on Phosgene Specialty Chemicals for Pharma and Agro

Paushak Q4 results FY26 reported net profit of Rs 12.51 crore for the quarter ended March 31, 2026. Paushak Q4 results reflect the company’s niche position as one of India’s few manufacturers of phosgene-based specialty chemicals, serving the pharmaceutical and agrochemical sectors with intermediates and fine chemicals that require specialised handling and manufacturing expertise.

Paushak Q4 results are reported as part of the Alembic Group, which provides strategic oversight and synergies in the hazardous specialty chemicals manufacturing space. The Paushak Q4 results business model is characterised by high barriers to entry from regulatory approvals for phosgene manufacturing, specialised plant and safety infrastructure, and long-standing relationships with domestic and international pharmaceutical and agrochemical companies.

Get Free Stock Recommendations on Univest

Paushak Q4 FY26 Results at a Glance

Metric	Q4 FY26	Change / Context
Q4 PAT	Rs 12.51 crore	Specialty phosgene chemicals
Group	Alembic Group company	Strategic support and synergies
Core Chemistry	Phosgene-based specialty	High barrier to entry
End Markets	Pharma and agrochemical	Stable demand base
Manufacturing	Hazardous chemical facility	Regulatory and safety moat

Track live Paushak financials, analyst ratings and peer comparisons on the Univest Screener.

Key Highlights from Paushak Q4 results

Phosgene Chemistry Barrier Creates Durable Moat in Paushak Q4 Results

Paushak Q4 results benefit from phosgene chemistry manufacturing which requires specialised regulatory approvals, safety infrastructure investment, and trained manpower that create significant barriers to new competition. The Paushak Q4 results moat is reinforced by customer stickiness, as pharmaceutical and agrochemical companies qualifying Paushak as a supplier through rigorous regulatory audits are unlikely to switch sources without significant validation cost. This makes Paushak Q4 results revenue highly predictable and recurring.

Pharma and Agro Demand Provides Stable Base for Paushak Q4 Results

Paushak Q4 results revenue is driven by domestic and export demand for phosgene-based intermediates from pharmaceutical API manufacturers and agrochemical companies. The Paushak Q4 results customer base includes established Indian and multinational pharma companies that use phosgene chemistry intermediates in regulated drug manufacturing. Agrochemical demand is also a steady source of Paushak Q4 results revenue.

What Drove Paushak Q4 FY26 Performance

Paushak Q4 results performance was driven by steady pharma API and agrochemical intermediate demand, high barriers to entry maintaining pricing power, and Alembic Group synergies providing shared infrastructure. The Paushak Q4 results unique phosgene chemistry position in a supply-constrained specialty chemicals niche allows consistent profitability despite being a small-scale company.

Outlook for FY27

Following Paushak Q4 results, FY27 outlook is stable with continued pharma and agro customer demand, potential capacity expansion to serve growing export opportunities, and Alembic Group strategic support. Paushak Q4 results position the company as a quality small-cap specialty chemicals compounder. Analyst targets for Paushak post Q4 results range Rs 12,000 to Rs 16,000.

Conclusion

Paushak Q4 results FY26 confirm PAT of Rs 12.51 crore on steady phosgene specialty chemicals demand. The regulatory moat, Alembic Group backing, and pharma-agro end market stability make Paushak Q4 results a consistent quality specialty chemicals performer. Track live data on the Univest Screener.

Download the Univest iOS App or Univest Android App for live Paushak Q4 results tracking and expert research.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before making investment decisions.

Frequently Asked Questions

What was the Paushak Q4 results FY26 net profit?

Paushak Q4 results FY26 reported PAT of Rs 12.51 crore from phosgene-based specialty chemicals manufacturing for pharmaceutical and agrochemical industry customers, supported by the Alembic Group.

What does Paushak make and why does it matter for Q4 results?

Paushak Q4 results are driven by phosgene-based specialty chemicals used as intermediates in pharmaceutical API manufacturing and agrochemical synthesis. Phosgene chemistry creates high entry barriers from regulatory and safety requirements.

What is the Alembic Group connection in Paushak Q4 results?

Paushak Q4 results benefit from Alembic Group membership, which provides strategic oversight, shared infrastructure, and synergies with Alembic Pharmaceuticals for specialty chemical procurement and R&D support.

What is the outlook after Paushak Q4 results FY26?

Following Paushak Q4 results, FY27 outlook is stable with pharma and agro demand continuing. Potential capacity expansion for export opportunities is a medium-term value driver. Analyst targets range Rs 12,000 to Rs 16,000 for Paushak post Q4 results.

Recent Article

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026

Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026

Why Is PSP Projects Share Price Falling Key Reasons 2026